Glenmark Pharmaceuticals Inc., USA, has announced the launch of its Authorized Generic version of INLYTA® (axitinib) tablets, available in 1 mg and 5 mg strengths. This move aims to increase access to affordable cancer treatment in the United States. The launch follows the significant U.S. annual sales of INLYTA®, which reached approximately $538.4 million in the 12 months ending September 2026.
Glenmark Pharmaceuticals Inc., USA Launches Authorized Generic INLYTA® Tablets
Glenmark Pharmaceuticals Inc., USA, today announced the launch of Axitinib Tablets, 1 mg and 5 mg. These tablets represent an Authorized Generic version of INLYTA® (axitinib) tablets, a medication used in cancer treatment. This launch is part of Glenmark’s strategy to enhance patient access to quality and affordable medicines.
Market Impact and Sales Data
The company highlighted that according to IQVIA® sales data for the 12-month period ending September 2026, the U.S. annual sales for INLYTA® Tablets were approximately $538.4 million. The introduction of an authorized generic is expected to provide a more cost-effective option for patients in the United States.
Strategic Commitment
Marc Kikuchi, President & Business Head, North America at Glenmark, stated, “The launch of Axitinib Tablets reinforces Glenmark’s commitment to expanding access to quality, affordable medicines for patients in the United States. By adding this important product to our portfolio, we continue to strengthen our focus on addressing the evolving needs of patients and healthcare providers.”
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. is a global, research-led pharmaceutical company focused on innovation and accessibility. With a diversified portfolio across branded, innovative, generics, and consumer health products, the company operates 11 manufacturing facilities and six R&D centers across four continents, serving over 80 countries. Glenmark is recognized among the Top 100 biopharmaceutical companies globally by pharmaceutical sales.
Source: BSE